Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib DDI Study with Rosuvastatin in Healthy Participants
NCT05906836Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), thyroid cancer and 1 more, sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Rosuvastatin at Day 5 and Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Rosuvastatin at Day 5. Started Jul 2023; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancersolid tumor
Beyond the preview
Go deeper on NCT05906836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906836.